From Benefits Pro: “The median launch price of a new drug in the US soared from $2,115 in 2008 to $180,007 in 2021, a 20% annual inflation rate over the period, researchers at Harvard-affiliated Brigham and Women’s Hospital in Boston found.”
Contributing to these higher launch prices are the increased costs of drug marketing. And as the chart below shows, nearly 90% of drugmaker marketing spend goes towards rebates that often find their way into the pockets of PBMs in exchange for formulary access.

It’s also important to understand that just because a drug is new doesn’t mean it’s better. All the new drug has to do to get FDA approval is to show “statistical significance” compared to a placebo.
MedBen Rx comparative effectiveness is an effective way to combat high-cost drug marketing. We use evidence-based research to match your members with the right medications. And when new drugs are introduced, we evaluate cost vs. effectiveness.
Comparative effectiveness brings clinical research and employers together, to find the most effective drugs at the best cost. Learn how by calling MedBen Rx at 888-627-8683.